journal

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of MedicineNovo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

7 days ago
Clarivate Unveils the 2025 Journal Citation ReportsClarivate Unveils the 2025 Journal Citation Reports

Clarivate Unveils the 2025 Journal Citation Reports

50th Anniversary Year Sees Strengthened Focus on Research Integrity LONDON, June 18, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider…

2 weeks ago
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlignFutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign

FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign

MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and…

3 weeks ago